Log in to your Inderes Free account to see all free content on this page.

SenzaGen

6.60 SEK

+7.49 %

Less than 1K followers

SENZA

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+7.49 %

+1.54 %

+12.63 %

+22.22 %

-4.35 %

-7.69 %

-49.23 %

-53.52 %

-84.38 %

Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.

Market cap

194.73M SEK

Turnover

100.62K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

13.2.

2026

Annual report '25

All

Webcasts

Press releases

ShowingAll content types

Press release11/20/2025, 6:30 AM

SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan

Press release11/19/2025, 7:39 AM

BioStock: Video from SenzaGen's presentation at BioStock Life Science Summit 2025

Press release11/18/2025, 10:20 AM

UK signals shift to non-animal testing – new opportunities for SenzaGen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release11/12/2025, 6:30 AM

SenzaGen secures order worth SEK 2.5 million from leading global tech company

Press release11/10/2025, 6:30 AM

SenzaGen presents growth plan and strategic priorities at Capital Markets Day

Regulatory press release11/5/2025, 6:30 AM

SenzaGen’s interim report January–September 2025 | Growth and break-even in Q3

Press release10/29/2025, 7:30 AM

Invitation to the presentation of SenzaGen's Q3 2025 interim report

Press release10/3/2025, 6:00 AM

SenzaGen secures orders of SEK 1.3 million from a US-based world-leading chemical company

Press release9/18/2025, 6:00 AM

SenzaGen invites to Capital Markets Day in Stockholm on November 10, 2025

Press release8/22/2025, 6:30 AM

SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD® from a global leading U.S. pharmaceutical company

Regulatory press release8/20/2025, 5:30 AM

SenzaGen’s interim report January–June 2025 | Strong order intake and expanded OECD approval for GARD®skin

Press release8/14/2025, 6:30 AM

Invitation to the presentation of SenzaGen's Q2 2025 interim report

Press release6/30/2025, 6:30 AM

SenzaGen obtains expanded OECD approval for GARD®skin – further strengthens position in non-animal regulatory testing

Press release6/24/2025, 6:30 AM

SenzaGen receives new assignment worth 1.5 MSEK from RIFM for continued collaboration in photosensitization testing

Press release6/2/2025, 6:30 AM

SenzaGen receives new assignment from RIFM – confirms successful expansion of testing portfolio

Press release5/15/2025, 9:31 AM

Redeye: SenzaGen Q1 - Quarterly sales impacted by challenging market climate

Regulatory press release5/14/2025, 1:45 PM

Report from AGM of SenzaGen AB on 14 May 2025

Regulatory press release5/14/2025, 6:00 AM

SenzaGen’s interim report January–March 2025: High activity amid global turbulence – building for growth

Press release5/8/2025, 6:45 AM

Invitation to the presentation of SenzaGen's January-March 2025 interim report

Press release4/22/2025, 12:30 PM

FDA signals shift towards non-animal testing in the pharmaceutical industry – strengthens SenzaGen’s commercial potential

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.